These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 19103993)

  • 1. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway.
    Zhu W; Soonpaa MH; Chen H; Shen W; Payne RM; Liechty EA; Caldwell RL; Shou W; Field LJ
    Circulation; 2009 Jan; 119(1):99-106. PubMed ID: 19103993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.
    Zhu W; Zhang W; Shou W; Field LJ
    Cardiovasc Res; 2014 Jul; 103(1):81-9. PubMed ID: 24812279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
    Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
    Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant low-dose doxorubicin treatment and exercise.
    Sturgeon K; Schadler K; Muthukumaran G; Ding D; Bajulaiye A; Thomas NJ; Ferrari V; Ryeom S; Libonati JR
    Am J Physiol Regul Integr Comp Physiol; 2014 Sep; 307(6):R685-92. PubMed ID: 25009215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways.
    Ma J; Wang Y; Zheng D; Wei M; Xu H; Peng T
    Cardiovasc Res; 2013 Jan; 97(1):77-87. PubMed ID: 23027656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Over-expression of calpastatin aggravates cardiotoxicity induced by doxorubicin.
    Wang Y; Zheng D; Wei M; Ma J; Yu Y; Chen R; Lacefield JC; Xu H; Peng T
    Cardiovasc Res; 2013 Jun; 98(3):381-90. PubMed ID: 23455548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serine mutations in overexpressed Hsp27 abrogate the protection against doxorubicin-induced p53-dependent cardiac apoptosis in mice.
    Kanagasabai R; Karthikeyan K; Zweier JL; Ilangovan G
    Am J Physiol Heart Circ Physiol; 2021 Nov; 321(5):H963-H975. PubMed ID: 34477462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Astragalus polysaccharide restores autophagic flux and improves cardiomyocyte function in doxorubicin-induced cardiotoxicity.
    Cao Y; Shen T; Huang X; Lin Y; Chen B; Pang J; Li G; Wang Q; Zohrabian S; Duan C; Ruan Y; Man Y; Wang S; Li J
    Oncotarget; 2017 Jan; 8(3):4837-4848. PubMed ID: 27902477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress.
    Gratia S; Kay L; Potenza L; Seffouh A; Novel-Chaté V; Schnebelen C; Sestili P; Schlattner U; Tokarska-Schlattner M
    Cardiovasc Res; 2012 Aug; 95(3):290-9. PubMed ID: 22461523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity.
    Yoshida M; Shiojima I; Ikeda H; Komuro I
    J Mol Cell Cardiol; 2009 Nov; 47(5):698-705. PubMed ID: 19660469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HECT-Type Ubiquitin E3 Ligase ITCH Interacts With Thioredoxin-Interacting Protein and Ameliorates Reactive Oxygen Species-Induced Cardiotoxicity.
    Otaki Y; Takahashi H; Watanabe T; Funayama A; Netsu S; Honda Y; Narumi T; Kadowaki S; Hasegawa H; Honda S; Arimoto T; Shishido T; Miyamoto T; Kamata H; Nakajima O; Kubota I
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26796253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resolvin E1 protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress, autophagy and apoptosis by targeting AKT/mTOR signaling.
    Zhang J; Wang M; Ding W; Zhao M; Ye J; Xu Y; Wang Z; Ye D; Li D; Liu J; Wan J
    Biochem Pharmacol; 2020 Oct; 180():114188. PubMed ID: 32750329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted expression of cyclin D2 ameliorates late stage anthracycline cardiotoxicity.
    Zhu W; Reuter S; Field LJ
    Cardiovasc Res; 2019 Apr; 115(5):960-965. PubMed ID: 30423020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.
    Efentakis P; Varela A; Chavdoula E; Sigala F; Sanoudou D; Tenta R; Gioti K; Kostomitsopoulos N; Papapetropoulos A; Tasouli A; Farmakis D; Davos CH; Klinakis A; Suter T; Cokkinos DV; Iliodromitis EK; Wenzel P; Andreadou I
    Cardiovasc Res; 2020 Mar; 116(3):576-591. PubMed ID: 31228183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor II receptor-α is a novel stress-inducible contributor to cardiac damage underpinning doxorubicin-induced oxidative stress and perturbed mitochondrial autophagy.
    Pandey S; Kuo WW; Shen CY; Yeh YL; Ho TJ; Chen RJ; Chang RL; Pai PY; Viswanadha VP; Huang CY; Huang CY
    Am J Physiol Cell Physiol; 2019 Aug; 317(2):C235-C243. PubMed ID: 31116582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities.
    Li J; Wang PY; Long NA; Zhuang J; Springer DA; Zou J; Lin Y; Bleck CKE; Park JH; Kang JG; Hwang PM
    Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19626-19634. PubMed ID: 31488712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice.
    Shizukuda Y; Matoba S; Mian OY; Nguyen T; Hwang PM
    Mol Cell Biochem; 2005 May; 273(1-2):25-32. PubMed ID: 16013437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Amnion Membrane Proteins Prevent Doxorubicin-Induced Oxidative Stress Injury and Apoptosis in Rat H9c2 Cardiomyocytes.
    Faridvand Y; Haddadi P; Vahedian V; Nozari S; Nejabati HR; Pezeshkian M; Afrasiabi A; Safaie N; Jodati A; Nouri M
    Cardiovasc Toxicol; 2020 Aug; 20(4):370-379. PubMed ID: 32086724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes.
    Feridooni T; Hotchkiss A; Remley-Carr S; Saga Y; Pasumarthi KB
    PLoS One; 2011; 6(7):e22801. PubMed ID: 21829519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotective roles of sestrin 1 and sestrin 2 against doxorubicin cardiotoxicity.
    Li R; Huang Y; Semple I; Kim M; Zhang Z; Lee JH
    Am J Physiol Heart Circ Physiol; 2019 Jul; 317(1):H39-H48. PubMed ID: 31026186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.